Incyte Corporation (INCY): Price and Financial Metrics


Incyte Corporation (INCY)

Today's Latest Price: $104.76 USD

3.11 (-2.88%)

Updated Jul 10 6:55pm

Add INCY to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 338 in Biotech

See all "A" rated Strong Buy stocks

INCY Stock Summary

  • The ratio of debt to operating expenses for Incyte Corp is higher than it is for about just 6.45% of US stocks.
  • With a year-over-year growth in debt of 191.23%, Incyte Corp's debt growth rate surpasses 92.52% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Incyte Corp is reporting a growth rate of -222.19%; that's higher than merely 8% of US stocks.
  • Stocks that are quantitatively similar to INCY, based on their financial statements, market capitalization, and price volatility, are BGNE, SGEN, GMAB, XLRN, and EIDX.
  • Visit INCY's SEC page to see the company's official filings. To visit the company's web site, go to www.incyte.com.
INCY Daily Price Range
INCY 52-Week Price Range

INCY Stock Price Chart Technical Analysis Charts


INCY Price/Volume Stats

Current price $104.76 52-week high $110.36
Prev. close $107.87 52-week low $62.48
Day low $104.54 Volume 794,600
Day high $108.17 Avg. volume 1,829,731
50-day MA $99.49 Dividend yield N/A
200-day MA $86.33 Market Cap 22.77B

Incyte Corporation (INCY) Company Bio


Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. The company was founded in 1991 and is based in Wilmington, Delaware.


INCY Latest News Stream


Event/TimeNews Detail
Loading, please wait...

INCY Latest Social Stream


Loading social stream, please wait...

View Full INCY Social Stream

Latest INCY News From Around the Web

Below are the latest news stories about Incyte Corp that investors may wish to consider to help them evaluate INCY as an investment opportunity.

Here's Why Incyte Rose 19.1% in the First Half of 2020

Shares of Incyte (NASDAQ: INCY) rose more than 19% in the first six months of the year, according to data provided by S&P Global Market Intelligence. After struggling to commercialize pipeline assets in recent years and diversify revenue away from Jakafi, Incyte appears to be making tangible progress with its late-stage pipeline. Wall Street appears a little more willing to buy into the company's growth pitch, which rests on a solid foundation provided by the Jakafi franchise.

Yahoo | July 9, 2020

Were Hedge Funds Right About Incyte Corporation (INCY)?

We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]

Yahoo | July 8, 2020

These 3 Biotech Stocks Are Outperforming Their Peers — Here's Why

The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth.

Yahoo | July 7, 2020

Incyte Announces Approval of Tabrecta™ (capmatinib) in Japan for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with METex14

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Approval of Tabrecta™ (capmatinib) in Japan for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with METex14

Business Wire | June 29, 2020

Gilead's (GILD) Remdesivir Gets CHMP Approval Recommendation

Gilead's (GILD) experimental coronavirus drug, remdesivir, has been recommended for approval by the EMA's human medicines committee.

Yahoo | June 26, 2020

Read More 'INCY' Stories Here

INCY Price Returns

1-mo 13.78%
3-mo 14.77%
6-mo 30.07%
1-year 30.79%
3-year -21.98%
5-year -9.60%
YTD 19.97%
2019 37.32%
2018 -32.86%
2017 -5.55%
2016 -7.54%
2015 48.34%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.1791 seconds.